Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $121M (up 80.1% year over year) with net income of −$22M.
Q3 2026 key financials · XBRL
- Revenue
- $121M
- +80.1% YoY · +22.3% QoQ
- Net income
- −$22M
- +75.6% YoY · +52.9% QoQ
- Operating margin
- -19.7%
- EPS (diluted)
- −$0.05
- +80.0% YoY · +50.0% QoQ
Source: XBRL data from the IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Q3 2026 10-Q on SEC EDGAR. USD.
IOVANCE BIOTHERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $121.5M, up 80% YoY from $67.5M, driven by Amtagvi $101.6M versus $57.5M
- Proleukin revenue $19.9M, up from $10.0M YoY, the fastest product growth at 99%
- Net loss $22.3M versus $91.3M YoY, with total costs and expenses $145.4M versus $162.4M
- Cash, equivalents, investments and restricted cash $382.3M, including $318.4M in short-term investments
- Operating cash outflow $137.4M for nine months, with $87.9M quarterly net proceeds from stock sales
Risk Factors
- New UPS/DDLPS registrational trial commenced in Q2 2026, increasing clinical execution and regulatory approval risk
- Manufacturing centralized at iCTC after Minaris exit in January 2026, creating near-term capacity and supply continuity risk
- FDA accelerated approval for Amtagvi requires confirmatory TILVANCE-301 Phase 3 trial, with failure threatening full approval
- Cash resources $382.3 million versus $148.6 million net loss for nine months ended September 30, 2026
- OBBBA changes may reduce ACA Marketplace and Medicaid coverage, potentially constraining reimbursement and product access
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IOVANCE BIOTHERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.